Middle East and Africa (MEA) Flu Diagnostic and Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory), And By Country - Forecasts From 2022 To 2027

The Middle East and Africa (MEA) flu diagnostic and treatment market is expected to surge at a CAGR of 10.89% throughout the forecast period. The market is projected to reach a value of US$7,045.595 million by 2027, from US$3,416.657 million in 2020.

The growing investments in the healthcare sector are one of the prime drivers for the Middle East and Africa (MEA) flu diagnostics and treatment market growth. Furthermore, increasing government support to boost the healthcare sector and improve the quality of healthcare across the numerous countries in the region is also contributing to the market growth for flu diagnostic and treatment in the Middle East and Africa (MEA) region. For instance, the government of Saudi Arabia is taking numerous initiatives to boost the private healthcare sector of the country as their inclination towards economic diversification and also to reduce the dependence on the public sector is also one of the key factors which is anticipated to propel the growth opportunities for the market to surge in the Middle East and Africa region throughout the forecast period and beyond. Furthermore, in many countries, the unavailability of well-established public healthcare is leading to the rising adoption of private healthcare services, such as in South Africa and Iran, among others. The growth in private health spending in numerous countries is also projected to show propelling growth opportunities during the coming years. For instance, in Israel, the proportion of private spending reached around 40% (Source: Israel Central Bureau of Statistics). This, in turn, is projected to augment the demand for advanced healthcare services, thereby positively impacting the market growth in the Middle East and Africa region.

Rising healthcare expenditure is expected to drive the market growth

Healthcare expenditure plays an important role in driving the flu diagnostic and treatment market in the region. The rising healthcare expenditure in various countries in the region further shows the potential for the market to grow as the rising healthcare expenditure indicates an increase in the demand for costly medical services and treatments, which is positively impacting the market growth for the coming years. For instance, according to the World Bank Group, the current healthcare expenditure per capita (current US$) in Israel reached US$2,387.14 in 2016 from 1,580.635 in 2006. Similarly, in Saudi Arabia, it increased from US$554.256 in 2006 to US$1,147.333 by 2016. In addition, the country also allocated around US$39.2 million in 2018, especially for the Healthcare and Social Development Sector, an increase of 10% from the previous year, which is also amplifying the market growth in the region throughout the forecast period.

Type A flu holds a notable share in the market

On the basis of the type of flu, the Middle East and African flu diagnostic and treatment markets have been classified into Type A and Type B. The Type A segment is anticipated to hold a noteworthy market share due to the fact that this is the most common type of influenza virus diagnosed throughout the various countries of the Middle East and Africa region. In addition, the number of diagnosed cases with type the flu is also higher in comparison with the number of type B flu in the region which is one of the key factors supporting the growth of the type A segment.

Qatar is anticipated to show noteworthy growth over the forecast period

On the basis of the country, the Middle East and Africa flu diagnostic and treatment market has been segmented on the basis of Saudi Arabia, Israel, UAE, Qatar, Iran, and South Africa, among others. Qatar is projected to show noteworthy growth in the market throughout the next five years due to the well-established healthcare sector and highly advanced healthcare infrastructure of the country. Israel is also projected to show decent growth during the forecast period as the country’s focus on providing quality healthcare to everyone supports the flu diagnostic and treatment market growth in Israel.

Key Developments in the Market

• In September 2020, The Ministry of Health and Prevention, MoHAP, has begun its yearly National Seasonal Flu Awareness Campaign 2020, which ran through the end of January 2021, with the slogan "Immunize yourself, Protect your community." The campaign, which was organised in collaboration with the Abu Dhabi Health Services, Abu Dhabi Public Health Centre, and Dubai Health Authority, aims to raise awareness of the value of receiving a seasonal flu vaccination and familiarize medical professionals with the most effective global practices for reducing the risks associated with the influenza virus.
• Based on best practices and lessons discovered during the COVID-19 response, Jordan examined and upgraded the risk communication and community engagement (RCCE) plan for pandemic influenza preparedness.  Between December 7 and 9, 2021, the Ministry of Health hosted a workshop to examine the strategy with technical assistance from the WHO country office in Jordan and the WHO Regional Office for the Eastern Mediterranean. Thirty-five people from the Royal Health Awareness Society, Jordan Food and Drug Administration, Ministry of Health, and Ministry of Agriculture participated in the event.
• In March 2021, in preparation for the upcoming winter season and seasonal flu, MediRite announced the availability of the 2021 flu vaccines across 146 sites, with prices starting at just R109. MediRite's portfolio covered four flu strains of the seasonal flu virus.

COVID-19 Impact on Middle East and Africa (MEA) Flu Diagnostic and Treatment Market:

COVID-19 had a positive impact on the Middle East and Africa Flu Diagnostics and Treatment market. The swift taken by the respective local government to have the population receive flu vaccines in order to prevent the seasonal flu from spreading amid the prevailing pandemic added impetus to the market growth. The initiatives taken MoHAP, as mentioned above, is the best example of this. Additionally, because COVID and influenza share many of the same symptoms, there was an upsurge in the need for SARS-CoV-2 and influenza diagnostic kits. Such elements had a favourable impact on the market.

Middle East and Africa (MEA) Flu Diagnostic and Treatment Market Scope:

Key Market Segmentation

• By Type of Flu
  • Type A
  • Type B
• By Offering
  • Diagnostics
    • Rapid Influenza Diagnostic Test
    • Rapid Molecular Assay
    • Others
  • Therapeutics
• By Age Group
  • 0-14 Years
  • 15-64 Years
  • >=65 Years
• By End-User
  • Hospital Laboratory
  • Outpatient Clinic
  • Reference Laboratory
• By Country
  • Saudi Arabia
  • Israel
  • UAE
  • Qatar
  • Iran
  • South Africa
  • Others

F. Hoffmann-La Roche Ltd

Thermo Fisher Scientific

3M

SA Scientific

Meridian Bioscience